Third Harmonic Bio Inc.

NASDAQ THRD

Data sourced from

and

Download Data

Third Harmonic Bio Inc. Capital Expenditure To Sales 3 year CAGR for the year ending September 20, 2024

Third Harmonic Bio Inc. Capital Expenditure To Sales 3 year CAGR is NA for the year ending September 20, 2024. The capital expenditure ratio measures the proportion of a company's revenue allocated to capital expenditures. It is calculated by dividing capital expenditures by revenue. This ratio indicates the extent to which a company invests in long-term assets relative to its sales. A higher ratio suggests a higher level of investment in the expansion and improvement of the company's asset base. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

NASDAQ: THRD

Third Harmonic Bio Inc.

CEO	Ms. Natalie C. Holles
IPO Date	Sept. 14, 2022
Location	United States
Headquarters	300 Technology Square, Cambridge, MA, United States, 02139
Employees	31
Sector	Healthcare
Industry	Biotechnology

Description

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.

Key trends